AnaptysBio (ANAB) earnings history
Most recent quarter
- Fiscal period
- Q4 2026
- Period end
- Jun 30, 2026
- EPS actual
- $5.11
- EPS estimate
- −$0.47
- EPS surprise
- +1198.92%
- Revenue surprise
- +95.54%
- Revenue
- $27.5M
- Revenue estimate
- $14.1M
- Reported
- Sep 21, 2026
AnaptysBio's latest entry, labelled Q4 2026 and covering the period to June 30, 2026, was reported on September 21, 2026. It posted earnings of $5.11 per share against an expected loss of $0.47, a surprise of 1198.92%. Revenue was $27.5 million, 95.54% above the $14.1 million estimate. The previous row in the table is Q2 2025, which ended a year earlier and showed a loss of $1.34 per share on $22.3 million of revenue.
The record is irregular: there are no rows between Q2 2025 and the latest entry, and its labels change at that point. Before it, AnaptysBio reported a loss in every quarter back to Q1 2021. Annual losses were $2.10 per share in 2021, $4.57 in 2022, $6.08 in 2023 and $5.21 in 2024. Quarterly revenue swung widely, from under $1 million in Q1 2022 to $43.1 million in Q4 2024. The only other profit was $1.20 per share in Q4 2020. It beat EPS estimates in 11 of these 20 entries.
With the gap and the change in period labels, past report dates are no reliable guide to the next report. The next entry will show whether the latest profit was a one-off.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q4 2026 | Sep 21, 2026 | −$0.47 | $5.11 | +1198.92% | $27.5M | SEC |
| Q2 2025 | Aug 6, 2025 | −$1.55 | −$1.34 | +13.59% | $22.3M | SEC |
| Q1 2025 | May 5, 2025 | −$1.25 | −$1.28 | −2.15% | $27.8M | SEC |
| Q4 2024 | Feb 27, 2025 | −$1.62 | −$0.72 | +55.54% | $43.1M | SEC |
| Q3 2024 | Nov 5, 2024 | −$1.65 | −$1.14 | +30.78% | $30.0M | SEC |
| Q2 2024 | Aug 5, 2024 | −$1.04 | −$1.71 | −64.30% | $11.0M | SEC |
| Q1 2024 | May 9, 2024 | −$1.57 | −$1.64 | −4.71% | $7.2M | SEC |
| Q4 2023 | Mar 11, 2024 | −$1.60 | −$1.59 | +0.67% | $9.0M | SEC |
| Q3 2023 | Nov 2, 2023 | −$1.78 | −$1.41 | +20.65% | $3.3M | SEC |
| Q2 2023 | Aug 7, 2023 | −$1.70 | −$1.50 | +11.53% | $3.5M | SEC |
| Q1 2023 | May 11, 2023 | −$1.03 | −$1.58 | −53.09% | $1.4M | SEC |
| Q4 2022 | Mar 1, 2023 | −$0.96 | −$0.93 | +2.82% | $6.8M | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.62 | −$1.18 | −89.68% | $1.3M | SEC |
| Q2 2022 | Aug 8, 2022 | −$0.98 | −$1.15 | −17.11% | $1.2M | SEC |
| Q1 2022 | May 4, 2022 | −$0.99 | −$1.31 | −31.67% | $970,000.00 | SEC |
| Q4 2021 | Mar 7, 2022 | −$0.99 | −$1.18 | −19.19% | $1.0M | SEC |
| Q3 2021 | Nov 4, 2021 | −$0.85 | −$0.24 | +71.77% | $20.9M | SEC |
| Q2 2021 | Aug 9, 2021 | −$0.10 | −$0.02 | +80.54% | $30.0M | SEC |
| Q1 2021 | May 4, 2021 | −$0.69 | −$0.66 | +4.11% | $11.2M | SEC |
| Q4 2020 | Feb 25, 2021 | $1.94 | $1.20 | −38.22% | $60.0M | SEC |
Quarterly revenue
Frequently asked questions
When did AnaptysBio (ANAB) last report earnings?
AnaptysBio last reported on Sep 21, 2026, covering fiscal Q4 2026.
Did ANAB beat earnings estimates?
Yes. AnaptysBio reported EPS of $5.11 for Q4 2026 against a −$0.47 estimate — a 1198.92% beat.
How much revenue did ANAB report last quarter?
AnaptysBio reported $27.5M in revenue for Q4 2026, against a consensus estimate of $14.1M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.